分泌IL-18的多抗原靶向CAR T细胞在免疫健全小鼠模型中清除抗原低表达骨髓瘤
该研究在免疫健全小鼠骨髓瘤模型中,发现靶向BCMA和BAFF-R的CAR T细胞在抗原弱表达时无法清除骨髓瘤,而分泌IL-18的CAR T细胞可促进骨髓瘤清除;同时靶向弱表达的BCMA和BAFF-R的双CAR T细胞增强T细胞与靶细胞亲和力、增加整体CAR信号强度并刺激抗骨髓瘤活性,且增强工程化IL-18分泌、促进清除体内较大骨髓瘤负荷。
要点
- 靶向BCMA和BAFF-R的CAR T细胞在抗原弱表达时未能清除骨髓瘤。
- 分泌IL-18的CAR T细胞促进弱表达抗原的骨髓瘤清除。
- 同时靶向弱表达的BCMA和BAFF-R的双CAR T细胞增强抗骨髓瘤活性。
核心结论
- 工程化IL-18分泌联合多抗原靶向可通过不同机制清除抗原弱表达的骨髓瘤。
研究设计与样本
- 在免疫健全小鼠骨髓瘤同基因模型中开展研究。
主要发现
- 靶向BCMA和BAFF-R的CAR T细胞在抗原弱表达时未能清除骨髓瘤,而分泌IL-18的CAR T细胞靶向这些抗原促进骨髓瘤清除。
- 分泌IL-18的CAR T细胞呈现效应样T细胞表型,促进干扰素-γ产生,通过I/II型干扰素信号重编程骨髓瘤骨髓微环境,并激活巨噬细胞介导抗骨髓瘤活性。
- 同时靶向弱表达的BCMA和BAFF-R的双CAR T细胞增强T细胞与靶细胞亲和力,增加整体CAR信号强度,并刺激抗骨髓瘤活性。
- 双抗原靶向增强CAR T细胞工程化IL-18分泌,并促进清除体内较大骨髓瘤负荷。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma is a plasma cell malignancy that is currently incurable with conventional therapies. Following the success of CD19-targeted chimeric antigen receptor (CAR) T cells in leukemia and lymphoma, CAR T cells targeting B-cell maturation antigen (BCMA) more recently demonstrated impressive activity in relapsed and refractory myeloma patients. However, BCMA-directed therapy can fail due to weak expression of BCMA on myeloma cells, suggesting that novel approaches to better address this antigen-low disease may improve patient outcomes. We hypothesized that engineered secretion of the proinflammatory cytokine interleukin-18 (IL-18) and multiantigen targeting could improve CAR T-cell activity against BCMA-low myeloma. In a syngeneic murine model of myeloma, CAR T cells targeting the myeloma-associated antigens BCMA and B-cell activating factor receptor (BAFF-R) failed to eliminate myeloma when these antigens were weakly expressed, whereas IL-18-secreting CAR T cells targeting these antigens promoted myeloma clearance. IL-18-secreting CAR T cells developed an effector-like T-cell phenotype, promoted interferon-gamma production, reprogrammed the myeloma bone marrow microenvironment through type-I/II interferon signaling, and activated macrophages to mediate antimyeloma activity. Simultaneous targeting of weakly-expressed BCMA and BAFF-R with dual-CAR T cells enhanced T-cell:target-cell avidity, increased overall CAR signal strength, and stimulated antimyeloma activity. Dual-antigen targeting augmented CAR T-cell secretion of engineered IL-18 and facilitated elimination of larger myeloma burdens in vivo. Our results demonstrate that combination of engineered IL-18 secretion and multiantigen targeting can eliminate myeloma with weak antigen expression through distinct mechanisms.
引用
- Ng BD, Rajagopalan A, Kousa AI, et al. IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model. Blood. 2024. PMID: 38579288. doi:10.1182/blood.2023022293
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。